Target intelligence / Profile preview

Human immunodeficiency virus type 1 group-specific antigen polyprotein (Gag polyprotein) and polymerase polyprotein (Gag-Pol polyprotein) (Gag (for group-specific antigen polyprotein), Gag-Pol (for polymerase polyprotein))

Target
Gag (for group-specific antigen polyprotein), Gag-Pol (for polymerase polyprotein)
Molecular classification
Structural polyprotein, Enzyme polyprotein (includes protease, reverse transcriptase, integrase components)
01

Overview

The Gag polyprotein is a ~55 kDa multidomain protein comprising the matrix (MA), capsid (CA), nucleocapsid (NC), spacer peptides (SP1, SP2), and p6 domains. It orchestrates membrane targeting, oligomerization, RNA packaging, and budding of new virions. During HIV-1 replication, Gag is cleaved by the viral protease at five specific sites to yield its functional domains, an essential step for virion maturation and infectivity. The Gag-Pol polyprotein arises by ribosomal frameshifting during translation of Gag and includes the protease (PR), reverse transcriptase (RT), and integrase (IN) enzymes in addition to Gag domains. Gag and Gag-Pol are crucial for constructing the viral particle and for enzymatic functions that allow the virus to replicate its genome, integrate into the host, and mature into an infectious virion. Both are highly validated antiviral drug targets, with numerous classes of inhibitors designed to block their processing or enzymatic activities. The canonical names for these molecules are “Human immunodeficiency virus type 1 group-specific antigen polyprotein (Gag)” and “Human immunodeficiency virus type 1 polymerase polyprotein (Gag-Pol),” with the abbreviations Gag and Gag-Pol, respectively. They are not properly represented as a single target (“HIV-1 group-specific antigen polyprotein and polymerase polyprotein”), so this entry should be split for structured annotation.

Other names
Gag polyproteingroup-specific antigen (Gag)p55Gag-Pol polyproteinPol polyproteinPr160^Gag-Pol
02

Mechanism of action

Protease inhibitors block processing of Gag and Gag-Pol polyproteins, preventing maturation of infectious virions; Maturation inhibitors block specific cleavage events (e.g., CA-SP1); Reverse transcriptase inhibitors block viral DNA synthesis; Integrase inhibitors block integration of viral DNA into the host genome

03

Biological functions

Assembly and budding of viral particlesEncapsulation of RNA genomeMembrane targeting and curvature inductionProteolytic processing (by HIV protease)Enzymatic activities (protease, reverse transcriptase, integrase)
04

Disease associations

Infection (central to HIV-1 pathogenesis and AIDS development)
05

Safety considerations

Drug resistance due to polymorphisms in Gag, especially at the maturation inhibitor binding site (CA-SP1 region)Toxicity and side effects for protease and polymerase inhibitorsOff-target effects on host cell processes
06

Interacting drugs

HIV protease inhibitors (e.g., ritonavir, darunavir)

3 more in the full profile.

07

Biomarkers

Cleavage patterns of Gag (monitored as indicators of maturation inhibitor efficacy)

Beyond the preview

Go deeper on Human immunodeficiency virus type 1 group-specific antigen polyprotein (Gag polyprotein) and polymerase polyprotein (Gag-Pol polyprotein) (Gag (for group-specific antigen polyprotein), Gag-Pol (for polymerase polyprotein)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human immunodeficiency virus type 1 group-specific antigen polyprotein (Gag polyprotein) and polymerase polyprotein (Gag-Pol polyprotein) (Gag (for group-specific antigen polyprotein), Gag-Pol (for polymerase polyprotein)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call